Initial-Care Medical and Prescription Costs for Incident Metastatic versus Nonmetastatic Colorectal Cancer
This study highlights the substantial economic burden of mCRC, with medical and prescription costs nearly twice those of nonmetastatic cases. The findings underscore the financial and clinical benefits of early detection and timely intervention, reinforcing the importance of routine colorectal cancer screening to reduce late-stage disease incidence.
Authors
- Mai P. Nguyen (ORCID: https://orcid.org/0000-0001-6411-5163)
- David R. Lairson (ORCID: https://orcid.org/0000-0003-2285-0527)
- Todd C. Skaar (ORCID: https://orcid.org/0000-0002-3849-374X)
- Patrick O. Monahan (ORCID: https://orcid.org/0000-0001-9481-1995)
- Hyunwoo Koo (ORCID: https://orcid.org/0000-0002-7232-1511)
- Paul G. Yeh (ORCID: https://orcid.org/0000-0002-3865-3010)
- Chi M. Nguyen (ORCID: https://orcid.org/0000-0002-1582-1253)
- Travis S. Johnson (ORCID: https://orcid.org/0000-0002-4628-2256)
- Thomas F. Imperiale (ORCID: https://orcid.org/0000-0001-7586-1073)
- Hongmei Nan (ORCID: https://orcid.org/0000-0002-9957-616X)
- Victoria Lee Champion (ORCID: https://orcid.org/0000-0002-6153-0713)
Institutions
- Texas A&M Health Science Center (US)
- Indiana University Health (US)
- University of Indianapolis (US)
- Purdue University West Lafayette (US)
- Pacific Research Institute (US)
- Indiana Cancer Consortium (US)
- Richard M. Fairbanks Foundation (US)
- Indiana University Indianapolis (US)
- Indiana University School of Medicine
- Indiana University – Purdue University Indianapolis (US)
- The University of Texas Health Science Center at Houston (US)
- Bryan College (US)
- Stanford University (US)
Publication Details
- Journal
- Cancer Research Communications
- Published
- 2025-09-26
- DOI
- https://doi.org/10.1158/2767-9764.crc-25-0367
- Citations
- 1
- Primary Topic
- Economic and Financial Impacts of Cancer
- Type
- article
- Field-Weighted Citation Impact
- 3.13